Melanoma and other Skin Tumours

Sarcomas

ESMO Immuno-Oncology Congress 2017

Oncology Meeting Resources

07 Dec
- 10 Dec 2017,
Geneva,
Switzerland

ESMO Immuno Oncology Congress 2017 reflects ESMO’s commitment to providing oncologists who need to learn how to apply the latest research and standards of care in the immunotherapy of cancer with a comprehensive update in an environment rich with highly specialised professionals.

Presentations (slides) and webcasts are available to ESMO members according to the presenters' agreement to release them. Abstracts are open access. Congress attendees should access via the ESMO Conferences platform.Resources will be added as they become available.

BackgroundIdentifying determinants of response to cancer immunotherapy is critical for extending therapeutic benefit to more patients. Atezolizumab (anti–PD-L1) was approved in the US for the treatment...

BackgroundE7046 is a selective small molecule antagonist of the prostaglandin E2 receptor-type-4 that inhibits the differentiation of monocytic myeloid lineage cells towards a pro-tumorigenic phenotype in the TME.